|
1
|
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
|
J Clin Oncol
|
2003
|
3.88
|
|
2
|
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
|
Cancer
|
2003
|
2.78
|
|
3
|
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
|
Anesth Analg
|
2007
|
1.94
|
|
4
|
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
|
Pediatr Blood Cancer
|
2009
|
1.83
|
|
5
|
Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
|
J Clin Pharmacol
|
2007
|
1.42
|
|
6
|
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
|
Eur J Cancer
|
2005
|
1.36
|
|
7
|
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
|
Cancer
|
2005
|
1.33
|
|
8
|
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
|
Cancer
|
2003
|
1.30
|
|
9
|
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
|
Am J Gastroenterol
|
2003
|
1.17
|
|
10
|
Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity.
|
J Clin Pharmacol
|
2004
|
1.06
|
|
11
|
Predictors of adherence to triptans: factors of sustained vs lapsed users.
|
Headache
|
2009
|
1.02
|
|
12
|
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
|
Cancer
|
2002
|
1.02
|
|
13
|
Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant.
|
Curr Med Res Opin
|
2007
|
0.97
|
|
14
|
Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
|
Anesth Analg
|
2009
|
0.88
|
|
15
|
Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study.
|
Headache
|
2002
|
0.87
|
|
16
|
Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
|
Drugs Today (Barc)
|
2004
|
0.84
|
|
17
|
Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
|
Clin Ther
|
2009
|
0.81
|
|
18
|
Migraine strikes study: factors in patients' decision to treat early.
|
J Headache Pain
|
2009
|
0.75
|